Physician profile
Patrick M Travis
NPI 1104897099
$37,013.45
in general payments reported to CMS, 2019-2025
71 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $11K · 2021: $646 · 2022: $3,769 · 2023: $839 · 2024: $4,501 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Honoraria: $1,755 · Travel and Lodging: $1,696 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.76 |
| Honoraria | $1,755.00 |
| Travel and Lodging | $1,695.59 |
| Education | $172.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14,177.19 | 2019-2025 | Ninlaro |
| Karyopharm Therapeutics INC. | $4,830.67 | 2020-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $3,729.86 | 2020-2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $3,607.74 | 2019-2024 | |
| Celgene Corporation | $2,155.37 | 2019-2025 | Opdualag, Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $1,893.72 | 2020-2022 | |
| Epizyme, INC. | $1,391.18 | 2020 | |
| Janssen Biotech, INC. | $794.42 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Janssen Pharmaceuticals, INC | $465.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $399.77 | 2019-2025 | Keytruda |
| Amgen INC. | $281.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $268.31 | 2019-2024 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $244.41 | 2019-2025 | |
| Astellas Pharma US INC | $198.45 | 2019-2024 | Xtandi, Padcev |
| Eisai INC. | $141.55 | 2019-2024 |
Show all 69 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.